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SUMMARY 
This report details the initial validation of hits from a genome-scale RNAi fitness screen 
to reveal genes that showed a specific loss of fitness in vivo. Analyses of African 
trypanosome biology are often carried out in HMI culture medium which is rich in 
nutrients and may not necessarily be representative of the environments encountered 
in vivo. We reasoned that parasites in vivo are likely to display increased dependence 
upon certain nutritional pathways as well as defences against oxidative stress and 
innate immune attack. 
Prior to this project, the lab ran a genome-scale RNAi fitness-profiling screen in rats in 
order to address this question. Analysis of the resulting list of genes that displayed a 
specific loss-of-fitness in vivo showed two genes linked to phosphatidylinositol 
metabolism, providing validation for the screen. Other hits included genes linked to 
folate metabolism and to DNA repair. 
This report details the initial analysis and validation of the hits from the screen and the 
development of systems for more detailed follow-up. One particularly promising 
approach described here is the growth of T. brucei in a simple serum system, which we 
believe effectively mimics aspects of the in vivo environment. Two genes were 
successfully validated, one of which has since been independently confirmed in the 
literature, and initial investigations into the underlying biology behind their 
phenotypes are described. The appendices to this report provide further detail 
regarding the hits from the in vivo screen, as well as describing two other projects 
which I worked on during my time in David Horn’s laboratory.  
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INTRODUCTION 
TRYPANOSOMES AND DISEASE 
THE TRYPANOSOMATIDS 
The African trypanosomes belong to a group of kinetoplastid protozoans known as the 
trypanosomatids. Several trypanosomatids are parasitic, mono-flagellated organisms 
with a ‘corkscrew-like’ shape (the name trypanosomatid comes from the Greek 
meaning ‘screw-borer body’1). They are a diverse and highly divergent group of 
eukaryotes with a variety of life cycles in both arthropod vectors and mammalian hosts 
and include several species which cause human disease2. As they are highly divergent 
from the main eukaryotic lineage, the trypanosomatids also contain a number of 
unique organelles such as the glycosomes3,4 and kinetoplasts5–9. 
There are three key neglected tropical diseases which are caused by trypanosomatid 
organisms, each spread by various biting insects. Spread by the sand fly, Leishmania 
spp. cause leishmaniasis, which presents in three forms: cutaneous, mucocutaneous 
and visceral. Of the three, the first shows the greatest morbidity, while the highest 
mortality is seen in the visceral form10. The South American trypanosome, 
Trypanosoma cruzi, causes Chagas disease and is spread by the triatomine bug. The 
African trypanosome, Trypanosoma brucei, is the focus of this project. It causes Human 
African Trypanosomiasis (HAT) and is spread by the bite of the tsetse fly. Collectively, 
these diseases cost thousands of lives in some of the poorest parts of the world and 
cause millions of pounds of economic damage. With existing drugs being 
 
 
 
 
 
unsatisfactory, even before current trends of emerging resistance, new treatments and 
diagnostics are desperately needed. 
THE AFRICAN TRYPANOSOMES 
Trypanosoma evansi was the first pathogenic trypanosome to be discovered (in horses 
and camels) in 1880. Fourteen years later, David Bruce identified Trypanosoma brucei 
as the causative agent of nagana in cattle11. Diagnosis of the African trypanosomes as 
the pathogen behind HAT followed in 1902. 
Trypanosoma brucei spp. are unicellular, obligate eukaryotic parasites with a complex 
life-cycle across both insect vectors and mammalian hosts (Figure 1). The procyclic 
form of the parasite replicates in the midgut of various Glossina spp., the tsetse fly. It 
then migrates to the insect’s salivary glands – morphing into the metacyclic form. This 
form is primed for infection by the generation of the surface coat which protect the 
parasite from immune-mediated clearance. When the tsetse takes blood from the 
mammalian host, the parasites are subdermally injected into the host. They proliferate 
at the site of infection, differentiating into long, slender bloodstream forms which 
migrate to the vasculature while a population remains in the skin to be taken up in 
future tsetse blood meals, increasing transmission12. From the vasculature, the 
trypanosomes can then invade other organs, particularly the central nervous system 
(CNS). The migration of the parasites into the CNS triggers the second stage of the 
disease. The time elapsing before this migration is dependent on the sub-species of the 
parasite, taking a few weeks for T. b. rhodesiense but an average of a year and a half 
for T. b. gambiense13,14. Once the parasite is in the CNS, it causes the neuropsychiatric 
 
 
 
 
 
symptoms described below that gave the disease its common name: African sleeping 
sickness.  
 
 
 
 
 
FIGURE 1: THE TRYPANOSOMA BRUCEI LIFE CYCLE 
 
 
The Trypanosoma brucei life cycle. A simplified diagram showing T. brucei alternating between 
the insect vector and the mammalian host. Rapidly dividing forms of the trypanosome in each 
stage eventually differentiate into non-dividing quiescent cells which are adapted for arrival into 
the human host, in the case of metacyclics, or the insect vector, in the case of ‘stumpy form’ 
parasites. Diagram taken from 15, having been adapted from the original from Nature Reviews 
Microbiology 16 © (2006) Macmillan Publishers Ltd. 
  
 
 
 
 
 
TRYPANOSOMES AND THE HOST 
Sleeping sickness was first described in the 14th century and has taken a heavy toll on 
both humans and livestock in Africa over the centuries. Between 1896 and 1908, 
Human African Trypanosomiasis killed approximately one million people in what is 
now Zaire and the North shore of Lake Victoria. Due to concerted control efforts, and 
the rise of cheap insecticides such as DDT providing improved tsetse control, this 
dropped dramatically until in the 1970s it was estimated that the yearly incidence of 
new infections was only twenty thousand17. 
However, with the apparent retreat of the disease coinciding with upheaval and unrest 
in the affected countries, the political will to tackle African sleeping sickness was lost 
and the disease resurged. By 2001, reports estimated that in some areas within the 
Democratic Republic of Congo (the focal point for T. b. gambiense) the prevalence rate 
had risen to be in excess of 60% and the World Health Organisation described African 
trypanosomiasis as “truly a re-emerging infectious disease”17. More recent estimates 
place the number at approximately 300,000 people infected, with sixty million living in 
at-risk areas. This means a total of anywhere between ten and forty thousand deaths 
every year1,18 and it is suspected that these figures are underreported due to the lack 
of health infrastructure in affected areas and the social stigma associated with the 
disease19,20. Untold amounts of economic damage have also been caused by animal 
African trypanosomiasis (AAT), also known as Nagana, the cattle disease caused by T. 
b. brucei, which has been recently reviewed by Morrison et al.21 
  
 
 
 
 
 
THE DISEASE: SYMPTOMS 
As noted above, Human African Trypanosomiasis is a two-stage disease. Early illness is 
associated with symptoms which are non-specific and, as a result, the disease can be 
challenging to diagnose. These non-specific symptoms include fatigue, headaches, 
fever, general malaise and enlarged lymph nodes. The second stage has progressively 
worsening neuropsychiatric symptoms such as sleep disturbance which, if untreated, 
will eventually lead to coma and death22. The disease is considered to have a 100% 
fatality rate if untreated1,22 although some studies contradict this (reviewed in 14) and 
reports of infection-tolerant individuals continue to emerge. 
T. b. gambiense causes the most common form of trypanosomiasis, causing over 95% 
of recorded cases and appearing primarily in West and Central Africa. T. b. 
rhodesiense, which is the less common form, is endemic in East and Southern Africa. 
The reason for this limited geographical localisation is that, unlike T. b. gambiense, T. 
b. rhodesiense is zoonotic and requires an animal reservoir. Currently, the two 
continue to be largely geographically distinct from each other. However, migration of 
T. b. rhodesiense means that incidences of the two diseases are starting to overlap in 
Uganda1,23. It is also becoming increasingly obvious that there is substantial variation in 
disease progression even within the subspecies of the parasite, with T. b. rhodesiense 
infections in Uganda progressing much more rapidly than they do in Malawi, for 
example24. 
The two forms of the parasite complicate treatment, as T. b. rhodesiense is resistant to 
some of the safer drugs that can be used to treat T. b. gambiense HAT. Treatment is 
additionally complicated by the inability of some drugs to cross the blood-brain barrier. 
 
 
 
 
 
Further difficulties exist due to the limitations of the existing diagnostic testing 
methods. The Card Agglutination Test for Trypanosomiasis (CATT) is a serological test 
which determines whether patient antibodies can bind to and aggregate suspended 
trypanosome samples25. However, due to a number of limitations which have been 
extensively discussed in the literature, such as being unable to detect T. b. rhodesiense 
HAT, high production costs and the requirement for extensively trained specialist 
personnel to operate the test, various alternatives have been sought for CATT22,26–30. 
One promising solution is a simple, high-sensitivity, lateral-flow device. Some progress 
has been made towards developing such a tool. However, it has not yet reached 
widespread use in the field and would not negate the necessity of a lumbar puncture 
to determine the stage of the disease30–32. 
  
 
 
 
 
 
THE DISEASE: TREATMENT 
The main treatment of first-stage T. b. gambiense, Pentamidine, has remained the 
same for more than half a century despite the impracticality of delivering the required 
repeated intravenous infusions in a resource-poor setting33. The primary drug for T. b. 
rhodesiense-mediated trypanosomiasis is Suramin, a drug that was discovered in 1917 
and has a range of serious side effects such as nausea, severe abdominal pain, 
diarrhoea and vomiting34. Melarsoprol, which superseded other arsenic-based 
compounds in the 1950s,35 remains the only drug which can be used to treat late-stage 
T. b. rhodesiense. Unfortunately, the drug also causes encephalopathic syndrome in up 
to 10% of patients, half of whom die as a result. Positively, however, it is an extremely 
potent drug and displays an EC50 in the low nanomolar range36. 
These examples serve to show the huge dearth of successful research into the 
treatment of trypanosomiasis for much of the last hundred years. However, 
improvements are slowly being made. Eflornithine is a trypanostatic drug which was 
originally developed for cancer. Initially trialled alone, it required four daily infusions 
for two weeks – resulting in a 90% cure rate37. However, it has proven to be more 
effective, with reduced side-effects, when used in combination with nifurtimox, a drug 
used to treat Chagas disease38,39. This combination therapy is now the frontline 
treatment for late-stage disease caused by T. b. gambiense. There are also two drugs in 
the pipeline for HAT. The more advanced of these is fexinidazole, thought to be a 
prodrug which is rapidly metabolised in vivo to form sulfoxide and sulfone40, and which 
could be sufficient to cure HAT with once-daily doses. However, nifurtimox and 
fexinidazole have the potential for cross-resistance41. This illustrates the danger of 
 
 
 
 
 
relying on the targeting of a small selection of known pathways and the need to 
constantly look for untargeted pathways to target with new therapies in order to keep 
ahead of the rapidly adapting parasite. 
To date, there remains no prospect of a successful vaccine, and the various drugs that 
currently treat the disease are too dangerous to take as prophylactics. As a result, 
preventative measures are primarily focused on vector control. In the 1960s it looked 
as if trypanosomiasis could be controlled, if not eliminated. However, decolonisation, 
war and the loss of political will led to decades of neglect. This resulted in increasing 
numbers of new cases. The World Health Organisation responded with new efforts to 
treat and control the disease, new funding was made available and the pharmaceutical 
industry committed to the continued production of the existing drugs. The disease is 
now on track for eventual eradication1. However, as described above, this situation has 
arisen before.  
The threat of resurgence due to a loss of focus on eradication, or emerging resistance 
in the parasite, should not be understated. 
TRYPANOSOMES AND THE IMMUNE SYSTEM 
Unlike their close relatives, Trypanosoma cruzi and Leishmania spp., the African 
trypanosomes are strictly extracellular. As described above, they exist largely within 
the haemo-lymphatic and central nervous systems, while recent studies have shown 
that parasites can also be found in the skin and adipose tissue12,42. This means that 
they are exposed to the full immune activity of the host and must rely on extensive 
 
 
 
 
 
and highly efficient mechanisms of immune escape. These include evading and 
manipulating both the cellular and humoral host responses in order to survive. 
TRYPANOLYSIS 
Humans have trypanolytic factors which effectively lyse trypanosomes in the 
bloodstream43,44. The main such factor is apolipoprotein L1 (APO-L1). This forms a 
complex with various other factors, including a haptoglobin-related protein which is 
taken up by the trypanosome45. Although APO-L1 is the best-known trypanolytic factor 
there are also others which are less well understood46. These act as a front line of 
defence against trypanosomes, and people deficient in APO-L1 have been shown to be 
vulnerable to infection from trypanosome species such as T. evansi which do not 
normally infect humans47. The two human-infective forms of trypanosome, T. b. 
gambiense and T. b. rhodesiense, each has its own method of resistance to APO-L1. T. 
b. rhodesiense neutralises APO-L1 with the APO-L1 binding serum resistance 
associated (SRA) protein, a truncated Variant Surface Glycoprotein (VSG)48–50. In a 
similar fashion, the predominant sub-group of T. b. gambiense resists lysis through the 
binding of T. b. gambiense-specific glycoprotein encoded by the TgsGP gene51,52 and 
also by reduced uptake of APO-L1 due to a single nucleotide polymorphism in the 
haptoglobin–haemoglobin receptor (HpHbR)53–55. 
VSGS 
VSGs are the parasite’s primary defence against the host immune system. VSGs are 50-
60 kDa homodimers with varying sequences and a conserved tertiary structure. The 
VSG coat is comprised of five million VSGs which are attached to the plasma 
 
 
 
 
 
membrane with a glycosylphosphatidylinositol (GPI) anchor56. When the host raises an 
immune response to their highly immunogenic surface and clears the parasite, a small 
sub-population of trypanosomes will be expressing a different VSG on their surface. 
These parasites will be overlooked by the immune attack and will survive to continue 
to proliferate. This gives rise to the overlapping and repeating waves of immune 
clearance followed by rising parasitaemia that is characteristic of an African 
trypanosome infection (Figure 2). The parasite only expresses one of the 2000+ full or 
partial VSG genes at a time. This mono-allelic control is mediated through VSG 
exclusion protein 1 (VEX1)57, although the mechanisms are not yet fully understood. 
This is key in preventing the parasite from expressing multiple VSGs and maintaining its 
ability to ‘escape’ immune clearance. 
This is not the only role that VSGs play in defending the parasite from the host immune 
response. VSGs are also used by T. b. gambiense to inhibit activation of the alternative 
pathway of complement by masking the sites that would trigger activation of the 
pathway and impair the ability of the host to lyse the trypanosome58,59. The rapid VSG 
recycling system that the trypanosome has in place also clears surface-bound 
complement factors and antibodies60. VSGs can be released into the bloodstream 
during peak parasitaemia, scavenging complement factors and potentially allowing the 
survival of a minority of parasites by preventing antibody-mediated complement 
activation61,62. This latter ability is thought to be the reason why GPI-PLC, the enzyme 
that cleaves the GPI-anchor and releases the VSG, has been found to be non-essential 
in cell-culture but has an important role in virulence63,64.  
 
 
 
 
 
FIGURE 2: THE PATTERN OF PARASITAEMIA 
 
 
Overlapping waves of parasitaemia typical of an African trypanosome infection. As the parasite 
multiplies within the host bloodstream, the immune response produces antibodies which target 
the VSG expressed on the cell surface. However, alternative VSGs will be expressed on the 
surface of some of the parasites within the population. As the antibody response does not 
target these alternative VSGs, the parasites expressing them survive the antibody-mediated 
clearance and multiply within the bloodstream, causing the repeating waves of parasitaemia 
within the host that are typical of an African trypanosome infection. 
 
  
 
 
 
 
 
IMMUNOSUPPRESSION 
As well as this immune evasion by antigenic variation, trypanosome infections have 
been linked to general immunosuppression. The mechanisms by which the parasites 
induce this are not well understood65–67, but any immune suppression would obviously 
improve survival in the host. A couple of examples are better studied. In the initial 
stages of infection, one study showed that Trypanosoma brucei adenylate cyclase 
activity reduces the early innate defence of the host by inhibiting the synthesis of TNF-
α68, similarly to other pathogens such as Bacillus anthracis (the causative agent of 
anthrax)69, and allowing the parasite to establish an infection in the host. A recent 
study has also shown that excretion of indolepyruvate by trypanosomes may modulate 
the host inflammatory response. Indolepyruvate decreases macrophage glycolysis and 
Hif-1α production70. 
One puzzling question is how the trypanosome guards against immune recognition of 
the large, non-VSG components on the cell surface. Components such as the 
moderately abundant invariant surface glycoproteins71–73 or HpHbR mentioned above, 
are known to extend beyond the VSG surface and to be available for binding54,74. While 
it is known that T. b. gambiense HpHbR (as discussed above) is mutated in such a way 
as to reduce APO-L1 binding, it is not yet understood how it avoids antibody 
binding,54,75 although its low expression in T. b. gambiense may help53. Indeed this last 
factor, combined with localisation predominantly in the flagellar pocket, is thought to 
provide the most likely answer to the question of how the trypanosome avoids 
immune recognition76–78, although the hydrodynamic flow of bound receptors that 
rapidly recycles VSGs may also contribute60. 
 
 
 
 
 
Trypanosomes also have a range of methods to combat the adaptive immune 
response, such as impairing B-cell functionality and inducing early activation and 
polarisation of T-cells. These are beyond the scope of this study but are effectively 
reviewed by Stijlemans et al.79  
 
 
 
 
 
TRYPANOSOMES IN CULTURE 
As can be seen, the African trypanosome has a complex relationship with its host. In 
addition to the immune interactions detailed above, it appears that trypanosomes 
alter the biochemical activity and behaviour of their hosts80–82. It has even been noted 
that T. congolense-infected animals are more frequently bitten by tsetse flies than 
non-infected animals. Some have conjectured that this is due to trypanosome 
catabolites which are secreted in the urine of infected hosts to make the host more 
attractive to the tsetse fly83,84. T. brucei is also known to stimulate the production of 
interferon γ by host lymphocytes85. This is then capable of stimulating T. brucei 
proliferation86. 
During a trypanosome infection, the host’s physiology can be distinctly altered, so 
questions have been raised as to whether a culture medium can accurately reflect the 
complexities of the in vivo infection. It is known that several bacterial species express a 
different gene set in their mammalian hosts than in the culture flask87 and, for 
example, rates of adaptation to antibiotic resistance in Salmonella spp. and even the 
preferred mutations that confer resistance can vary from host to flask88. Could similar 
complexities exist with trypanosomiasis? 
THE DEVELOPMENT OF IN VITRO CULTURE 
Although earlier attempts are recorded89,90, 1967 is the first time that short-term 
culture in the presence of feeder cells was observed for T. brucei91. It took a further 
ten years before continuous propagation was observed92, also in the presence of 
feeder cells. However, this method only worked with the Lister 427 strain of T. brucei. 
 
 
 
 
 
The introduction of Minimal Essential Medium of Eagle (MEM) with supplemental 
amino acids, glutamine, embryonic fibroblast-like cells from the north American vole, 
and heat-inactivated human serum allowed the culture of other strains of T. brucei93,94. 
The recognition by Duszenko and colleagues in the Cross laboratory that 
supplementation with cysteine could eliminate the requirement for a feeder cell 
layer95 simplified culture techniques substantially. Further experimentation showed 
that the addition of reducing agents helped to stop this addition of cysteine from being 
toxic to the cells96. Cysteine was later shown to be an essential amino acid for 
trypanosomes97. 
In 1989, Hirumi and Hirumi published their paper detailing the HMI-11 medium which 
is still used in laboratories today98. Based on Iscove's modification of Dulbecco's MEM 
(IMDM) and adding a copper chelator to prevent the oxidation of cysteine, HMI-11 is a 
rich medium with a large overabundance of key nutrients. 
THE LIMITATIONS OF IN VITRO CULTURE 
This medium is foundational to most trypanosome experiments, including the screens 
used to find new drugs for trypanosomiasis. However, the medium is much richer than 
the actual situation in an infection in vivo (Table 1). This leads to several problems. For 
example, the high concentration of common metabolites means that it is difficult to 
observe metabolic alterations because of the large background pool. Drug-induced 
perturbations are also often missed due to the masking effect of compensatory 
mechanisms. Immune attack by the host is not present in culture, and it is reasonable 
to assume that several metabolic stresses are also missing from the standard culture 
system. There may well also be certain activities in rich culture media that are not 
 
 
 
 
 
relevant to the medical situation. The complex interactions described above where the 
trypanosome manipulates its host are also missing from the lab-based culture media. 
  
 
 
 
 
 
TABLE 1: KEY COMPONENTS OF HMI-11 COMPARED TO HUMAN BLOOD 
Component HMI recipe Human Blood Excess 
Glucose 25,000 4,817 5x 
L-Cysteine 1,504 99 15x 
L-Methionine 201 29 7x 
Hypoxanthine 1000 8 125x 
Folic Acid 9 0.03 300x 
Thymidine 161 0.2 805x 
Myo-inositol 40 24 1.6x 
Table showing levels of key components of HMI-11 compared to average levels in human blood. 
Adapted from Creek et al.99, data taken from the Human Metabolome Database100–102. All data 
in μM concentrations 
 
It is highly likely that many of the previous high-throughput screening approaches 
using the standard HMI-11 media may have underestimated the potency of many 
potential drugs, especially where those are connected to metabolic processes or 
immune evasion99. For example, this has been observed previously in the study of 
dihydrofolate reductase (DHFR)-thymidylate synthase inhibitors where it was shown 
that these inhibitors only show significant trypanocidal activity where folic acid is 
depleted103. 
Metabolomics has proved to be a useful tool for the rational optimisation of cell 
culture medium. Using this approach has led to media called Creek’s Minimal Media 
(CMM) which allows the screening of trypanocidal activity by established methods but 
in a medium that more closely represents metabolite concentrations in human 
blood99.  
 
 
 
 
 
THIS PROJECT 
RNAI SCREENS 
Genome-wide RNAi library screens have proved highly useful for probing trypanosome 
biology: in particular for elucidating drug resistance mechanisms104,105. An unpublished 
screen carried out in David Horn’s laboratory found 45 genes which were essential only 
in vivo. These hits form the basis for this project. The screen used an RNAi plasmid 
library comprised of randomly fragmented genomic DNA106 to create a library of 
inducible RNAi in bloodstream T. brucei. This was then used to determine essential 
genes as previously described for the published in vitro screen107. However, the 
trypanosomes were inoculated into rats rather than grown in culture flasks (Figure 3A).  
A control set of genes whose dispensability or essentiality was known to be the same 
both in vitro and in vivo was used to establish cut-off points to delineate the hits which 
were of interest. This gave a list of forty-five hits (Table 5; Appendix 1) which were 
essential in vivo while being dispensable in standard culture conditions. The screen has 
not been carried out in vivo before and therefore there is still extensive verification to 
be done in order to validate the data set. 
We expected to see a number of genes from categories such as innate immune 
defences, stress and metabolism as well as some which show overlapping functions 
within these categories (Figure 3B). We also expected to find some of the few proteins 
which have been previously shown in the literature to have an in vivo-specific function. 
We discovered genes which played a role in phosphatidylinositol signalling and in 
control of allelic exclusion, the method by which the parasite maintains the 
 
 
 
 
 
effectiveness of the VSG coat in avoiding immune clearance. These genes were 
inositol-1(or 4)-monophosphatase 2 (IMP)108, glycosylphosphatidylinositol-specific 
phospholipase C (GPI-PLC)64 and a histone-lysine N-methyltransferase (DOT1B)109. This 
was encouraging as it met our expectations. 
 
  
 
 
 
 
 
FIGURE 3: RNAI SCREEN DIAGRAM 
 
 
(A) Diagram of the RNAi screen showing RNAi library induced in both in vivo and in vitro 
situations. The dark blue and light blue populations represent genes essential or dispensable 
respectively in both the in vitro and in vivo scenarios. Green and red populations represent 
genes which are only essential in the in vitro and in vivo conditions respectively. The latter 
population is the one of interest for this project. (B) Expected categories of proteins which show 
a specifically in vivo essential phenotype. (C) Graphical representation of the results from the 
RNAi screen. The blue population shows control genes, many of which are associated with a 
fitness cost both in vitro and in vivo (intraflagellar transport, proteasome, nuclear pore, MCM2-
7 and coatomer components). Green and red populations represent genes which are only 
essential in the in vitro/in vivo conditions, respectively. 
  
 
 
 
 
 
AIMS AND OBJECTIVES 
My primary aim was to improve understanding of host:T. brucei interactions at the 
molecular level. In order to do this I aimed: 
- To analyse hits from the in vivo RNAi screen.  
- To develop a culture method more resembling the in vivo situation. 
- To use the new culture method to validate a small number of hits from the 
screen.  
 
 
 
 
 
EXPERIMENTAL PROCEDURES 
BIOINFORMATICS AND HIT PRIORITISATION 
In order to understand the function of products which were encoded by the genes on 
our hit list, the gene IDs were used to query the publicly available datasets on 
TriTrypDB110. Existing data on the function and characteristics of the gene products, 
such as conservation among trypanosomes, the number of predicted transmembrane 
domains and potential orthologues in other species, were compiled. Data from 
transcriptomic and proteomic studies analysing differential protein111 and RNA 
expression112 between T. brucei developmental stages were also considered, as it was 
thought likely that genes up-regulated in bloodstream forms were more likely to be 
genuinely involved in host:parasite interactions. 
BLAST113 was used to assign putative functions based on sequence similarity and to 
assess the conservation of each gene by searching the ‘all organisms’ database by gene 
and protein sequences and recording whether they were conserved only among the 
trypanosomes, among other parasites, or more broadly. Each hit was then searched 
against the NCBI Conserved Domain Database (CDD)114–116 to find any known domains 
which could inform function and assign potential pathways. 
 
  
 
 
 
 
 
STRAIN GENERATION  
Genomic DNA was isolated from bloodstream T. brucei using a DNeasy kit (Qiagen) 
according to the manufacturer’s instructions. From this genomic template, fragments 
of 400–600 bp targeting the genes of interest were amplified by high-fidelity Phusion 
polymerase (NEB) according to the manufacturer’s instructions (Figure 4A). These 
fragments were ligated overnight at 4oC using T4 ligase (NEB) according to 
manufacturer’s instructions in sense and antisense configurations (Figure 4E) to 
digested pRPaiSL (117) to generate inducible stem-loop RNAi constructs (Figure 4C, D). 
For tagging at the native loci, C-terminal fragments were amplified (Figure 5A) and 
cloned into pNATxTAG (117) (Figure 5C) and verified by western blot. PCR primers were 
designed using RNAit118 (Table 2). All oligonucleotides were synthesised by 
ThermoFisher Scientific. 
Bloodstream-form T. brucei 2T1 cells117 were transfected using a Nucleofector™ 2b 
(Lonza) with Cytomix. Clonal populations were generated by limiting dilution and 
selected with hygromycin (2.5 μg/mL) for RNAi constructs successfully integrated at 
the tagged locus and with blasticidin (10 μg/mL) for native tagging constructs (Table 3) 
according to the standard procedures117,119. 
  
 
 
 
 
 
TABLE 2: PRIMER SEQUENCES 
Primer Sequence Notes 
F_RNAi_5.2690 GATCGGGCCCGGTACCTGCGTCTCTATAGCCCTCGT Bsp1201 Acc651 5’ sequence 
R_RNAi_5.2690 GATCTCTAGAGGATCCTAGCTGCAACTCCCACTCCT Xba1 BamH1 3’ sequence 
F_RNAi_10.4260 GATCGGGCCCGGTACCTTCAGTGATCAGTCGCAAGG Bsp1201 Acc651 5’ sequence 
R_RNAi_10.4260 GATCTCTAGAGGATCCTGCAGCCTTTTATTGTGCAG Xba1 BamH1 3’ sequence 
F_RNAi_8.2610 GATCGGGCCCGGTACCCGGCGGTGCGATAAATGAGG Bsp1201 Acc651 5’ sequence 
R_RNAi_8.2610 GATCTCTAGAGGATCCCCGTTAATATGCCCTTCACT Xba1 BamH1 3’ sequence 
F_8.2610.12MYC GATCGGCGCGCCCATTGATTCCGACAACTACG Native tagging, AscI 
R_8.2610.12MYC GATCTCTAGAGTGCACAGTAAAGTGCCGCT Native tagging, XbaI 
F_5.2690.12MYC GATCAAGCTTATGCCAATAAATAACTGTGA Native tagging, HindIII 
R_5.2690.12MYC GATCTCTAGAGCATCCTAACACCGATTTTT Native tagging, XbaI 
Primer Sequences used in construct assembly.  
 
 
 
 
 
FIGURE 4: RNAI CONSTRUCT ASSEMBLY 
 
Assembly of RNAi constructs. 1: IMP. 2: 5-MetE. 3: Hyp-Con. (A) PCR products. All show 
expected sizes (approx. 1 – 500 bp, 2 – 550 bp, 3 – 600 bp). (B) Test digests. a: Acc65I, releasing 
stuffer and both inserts. b: Bsp1201 and XbaI, releasing second stage insert. All show expected 
sizes (approx. 1a – 1400, 5000; 1b – 400, 6000; 2a – 1500, 5000; 2b – 500, 6000; 3a –1700, 
5000; 3b – 600, 6000) (C) AscI digest to release construct for integration into parasite genome. 
From left to right: uncut control, IMP and Hyp-Con. (D) AscI digest. From left to right: MetE, 
uncut control.  (E) Diagram showing construct assembly. 
 
 
 
 
 
FIGURE 5: TAGGING CONSTRUCT ASSEMBLY 
 
 
(A) PCR for native tagging showing expected sizes. 1: MetE, 1010 bp. 2: IMP, 850 bp. (B) Test 
digests for the final constructs. 1a: IMP, MluI digest; 1, 4.2 kbp. 1b: IMP, AccI digest; 2.2, 2.9 
kbp. 2a: 5-MetE, SalI digest; 2.4, 2.9 kbp. 2b: 5-MetE, SspI digest; 2.1, 3.2 kbp. (C) Diagram 
showing construct design. BsmI site in both constructs is used to linearise the plasmid for 
integration into the genome at the target locus. BSD: Blasticidin resistance cassette.  
 
 
 
 
 
TRYPANOSOME CULTURE  
Initial tests were with trypanosomes grown in calf serum (Sigma) supplemented with 
bathocuproinedisulfonic acid (30 μM) and beta-mercaptoethanol (10 μl/L). Otherwise, 
trypanosomes were grown in HMI-1198, or calf serum (Sigma) supplemented with 
bathocuproinedisulfonic acid (30 μM) and thioglycerol (10 μl/L). Calf serum was 
filtered before supplementation where noted. Folate, thymidine and methionine-free 
media were prepared as per the standard HMI-11 recipe, with the omission of folic 
acid, thymidine, and methionine as appropriate. Cumulative growth curves were 
carried out using cultures seeded at 104 or 105 cells/mL as appropriate, counted on a 
haemocytometer (Neubauer) every 48 h or 24 h respectively, and diluted as necessary. 
Induction of RNAi constructs was by 1 μg/ml tetracycline. Transgenic parasites were 
selected for and maintained using the appropriate drug concentrations detailed in 
Table 3. Standard incubator conditions of 5% CO2 and 37oC were used for all cell 
culture. 
TABLE 3: DRUG CONCENTRATIONS 
 Construct Selection Maintenance 
Hygromycin RNAi 2.5 1 
Phleomycin All 1 0.2 
Blasticidin Tag 5 1 
Puromycin 2T1 2 1 
Drug concentrations used for selection and maintenance of bloodstream T. brucei. All 
concentrations in μg/ml. 
  
 
 
 
 
 
TAG AND PROTEIN ANALYSIS 
WESTERN BLOTTING 
1 x 107 cells were pelleted by centrifugation at 1,000 g for 10 minutes. HMI-11 was 
removed and the pellets were washed twice with 1x PBS to remove trace elements of 
media. Pelleted samples were then resuspended in SDS sample buffer at a 
concentration of 100,000 cells/μl and proteins denatured by boiling for 5 minutes. 
Protein samples were loaded equally on two 8% polyacrylamide gels and run at 150 V 
for approximately 90 minutes. One gel from each experiment was then fixed with 
isopropanol for 15 minutes, stained with coomassie blue (1-3 h) and destained 
overnight for a loading control. The second gel was soaked for 15 minutes in transfer 
buffer (48 mM Tris, 39 mM glycine, 20% Methanol, 0.0375% SDS) and transferred to 
nitrocellulose at 20 A for 20 min. 
Nitrocellulose membranes were blocked in 5% Marvel in TBS-T (0.05% Tween) 
overnight at 4oC. 12-myc tags were detected using 1:5000 dilutions of mouse anti-myc 
antibody (Source Bioscience) and 1:2000 dilutions of goat anti-mouse antibody 
(BioRad). 
IMMUNOFLUORESCENCE 
500 μl of log-phase culture was added to 500 μl 2% paraformaldehyde and incubated 
at 4oC for 1 h before being pelleted at 6000 rpm. Pellets were washed three times in 
ice-cold PBS before being resuspended in 1 ml 1% Bovine Serum Albumin and spotted 
on slides. 
 
 
 
 
 
After drying overnight, cells were washed in PBS and permeabilised using 0.5% Triton 
X-100 in PBS. The cells were then blocked in 50% FBS. 
12-myc tags were detected using mouse anti-myc antibody (Source Biosciences) 
diluted in 3% FBS and FITC labelled anti-mouse antibody (Thermo) diluted 1:100 in 3% 
FBS. VECTASHIELD® Antifade Mounting Medium with DAPI (Vector Laboratories) was 
used to mount the cells and stain the DNA.  
 
 
 
 
 
RESULTS 
RNAI SCREEN ANALYSIS 
We found seven genes for which homology and conserved domain searches indicate a 
role in metabolism. Three of these appear to have a role in Folate/Methionine 
metabolism. Five of the hits have a role in either cell cycle checkpoints or the stress 
response. Only three genes are thought to be linked to the immune system. However, 
the innate immune defence of the parasite has not been extensively studied. Given 
that the functions of eighteen out of the forty-five genes selected by this screen are 
completely unknown, there could be many new innate immune defence factors in this 
large section of the dataset. However, we did find two genes which are known to have 
a role in immune defence: GPI-PLC64 and DOT1B109. GPI-PLC is involved in releasing 
VSG into the bloodstream, while DOT1B is crucial in the modulation of antigenic 
variation and mono-allelic expression. The centrality of both of these to the parasites’ 
immune defence mechanisms is discussed further below. Lists of hits from each of the 
above categories and further information are shown in Appendix 1. 
A search of the dataset using TriTrypDB revealed 49% of the dataset to be annotated 
as being either hypothetical proteins or proteins containing a domain of unknown 
function. However, this was not a statistically significant difference compared to 35% 
when the same search was carried out against the whole genome (P = 0.0541). 
  
 
 
 
 
 
BIOINFORMATICS AND GENE PRIORITISATION  
In order to select hits from the in vivo RNAi screen described above for a pilot study, 
particular features were looked for such as the presence of a reasonable hypothesis as 
to why these genes proved dispensable in vitro and essential in vivo; conservation 
among the kinetoplastids; the presence of signal peptides or transmembrane domains 
(Table 5; Appendix 1: RNAi Screen Hits), indicative of the gene product being targeted 
for secretion or being external to the surface of the parasite; and lastly, the quality of 
the coverage in the RNAi screen (Figure 6). 
Examining this led us to prioritise three hits for initial validation. These hits were: 
Tb927.5.2690, a putative inositol monophosphatase (IMP) selected for its link to the 
parasite immune defence via myo-inositol synthesis; Tb927.8.2610, a putative 
methyltransferase (5-MetE), selected for its links to the crucial in vivo process of folate 
metabolism; and Tb927.10.4260 (Hyp-Con), a hypothetical protein selected for its large 
number of transmembrane domains and possible role in lipid transport. This latter 
possibility was highlighted by sequence similarity which indicated that the protein was 
similar to a known protein family containing a lipocalin transmembrane receptor. 
 
  
 
 
 
 
 
TABLE 4: PILOT GENES 
Name Gene ID # TM SignalP # Orthologues mRNA112 Proteome111 
IMP 5.2690 0 null 29 1.155 2.91 
5-MetE 8.2610 0 null 24 1.698 No data 
Hyp-Con 10.4260 10 0.9 23 No data 8.91 
Table showing known characteristics of the three genes chosen for pilot study. #TM describes 
the predicted number of transmembrane domains from the sequence. SignalP describes the 
probability of the gene containing a signal peptide for secretion/expression on the surface from 
sequence similarity to known signal peptides. #Orthologues shows the number of known 
orthologues to the gene across sequenced genomes. mRNA describes fold change in mRNA 
abundance (bloodstream/procyclic). Proteome describes fold change in protein abundance 
(bloodstream/procyclic) 
 
FIGURE 6: SEQUENCE READ MAPPING 
 
Sequence read mapping for the three hits pursued as part of this study. High-throughput RIT-
seq carried out for all five populations (uninduced, in vitro induced and 3x in vivo induced) and 
the data mapped by Axel Martinelli at Sanger according to previously described protocols120. 
Numbers for fold change refer to the difference between the average of the three in vivo 
induced populations and the in vivo induced sample. 
  
Uninduced 
in vivo (HMI9) 
in vitro (rat) 
5-MetE IMP Hyp-Con 
10.4 fold change 6.4 fold change 7.3 fold change 
 
 
 
 
 
GROWTH IN SERUM TO MIMIC THE IN VIVO ENVIRONMENT 
Previous work by Nicola Baker in this lab indicated linear growth of trypanosomes was 
achievable in FBS (Sigma) supplemented with a copper chelator, 
bathocuproinedisulfonic acid (30 μM); and a reducing agent, β-mercaptoethanol (14 
μl/L). However, this was not readily reproducible. 
I decided to test this and also whether the substitution of thioglycerol for the reducing 
agent in place of β-ME would be more reproducible. Following several attempts, with 
different batches of serum, I found that bathocuproinedisulfonic acid and thioglycerol 
(14 μl/L) provided stable and linear growth with the limitation that the parasites could 
not be seeded below 105 / ml and therefore required daily splitting. Parasites seeded 
at lower densities did not grow (data not shown). Serum with β-mercaptoethanol 
failed to show linear growth (Figure 7). I also tested Creek’s Minimal Media99. The test 
proved unsuccessful (Figure 7A), for reasons which remain unknown. 
More recent experiments indicated that the presence of cysteine (1.5 mM) in the 
culture medium provided faster and more stable growth. However, this was not 
reflected in the repeat experiments (data not shown). This difference may have been 
due to the different environment provided by using a plate instead of a flask to grow 
the cells in the former experiment. Further experiments are required to verify the 
impact of cysteine on the serum system.  
In order to confirm these results over a longer period, growth curves were set up to 
compare growth in HMI-11 with sterile filtered (in order to deal with a contamination 
issue) serum supplemented in three different ways. The cells were grown under 
 
 
 
 
 
standard conditions and were counted and split to 1x105 daily. The results (Figure 7B) 
showed that serum supplemented with bathocuproinedisulfonic acid and thioglycerol 
(14 μl/L) yields robust growth comparable to that in standard rich media conditions 
and which can be maintained over a six-day period. This simple serum medium was 
termed SS1 for the duration of the study. As sterile filtered serum appeared to provide 
superior growth (Figure 7B) compared to the initial tests with non-sterile filtered 
serum (Figure 7A), it was used for the remainder of the study. The reason for this 
effect is unknown; but it may be due to the removal of low-grade bacterial 
contaminants which were previously unobserved. Alternatively, it could simply be due 
to variation in serum batches. In order to control for this in future, the remainder of 
the batch was reserved for all future experiments using SS1. 
Other evidence from a course run by members of this lab at the Marine Biology 
Laboratory in Woods Hole, MA suggests that it is possible to grow trypanosomes in 
serum supplemented with beta-mercaptoethanol at a similar level to that shown in 
this report with thioglycerol-supplemented serum. We should, therefore, like to repeat 
this to address the question of whether these conflicting reports are due to variation 
between serum sources.  
 
 
 
 
 
FIGURE 7: ALTERNATIVE MEDIA DEVELOPMENT 
 
Graphs showing initial assessment of potential media for studying the hits from the in vivo 
screen. Two technical replicates using 2T1 wild-type cells were used for each condition in both 
experiments. Error bars show standard deviation from the mean of two independently 
generated biological clones. (A) Initial media assessment showing parasite growth in HMI-11, 
CMM and serum supplemented with β-ME or thioglycerol. (B) The growth of wild-type 
trypanosomes in HMI-11 and serum supplemented with β-ME or thioglycerol. In both 
experiments Serum +Thioglycerol: serum supplemented with bathocuproinedisulfonic acid (30 
μM) and thioglycerol (14 μl/L). Serum +BME: Replacement of thioglycerol with beta-
mercaptoethanol (14 μl/L).  
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RNAI TARGETING HYP-CON LEADS TO PARASITE DEATH IN HMI-11 
In order to discover whether the genes were required in vitro, RNAi strains were 
assembled and induced over a three-day period in HMI-11. This experiment showed 
that the hypothetical conserved protein encoded by Tb927.10.4260 was not a valid hit 
from the screen, as it showed a clear in vitro growth defect (Figure 8). Due to this, it 
was not of interest for this study and no further experiments with this gene are 
planned. 
The induction of RNAi targeting the putative inositol monophosphatase (IMP) showed 
no such growth defect, and the parasites grew the same both when induced and 
uninduced. At this stage, 5-MetE was not tested as the construct assembly was 
incomplete. Data for this gene is shown below (Figure 10). 
 
  
 
 
 
 
 
 
FIGURE 8: CUMULATIVE GROWTH OF RNAI STRAINS IN HMI-11 
 
Cumulative growth over 72 hours of two initial RNAi strains in HMI-11. Error bars show standard 
deviation from the mean of two independently-generated biological clones. 
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RNAI TARGETING IMP LEADS TO LOSS OF FITNESS IN SS1 
In order to test whether the phenotype was different in SS1 from the standard media 
conditions, two independent biological clones containing the inducible stem-loop 
construct targeting the putative inositol monophosphatase (IMP) gene were induced 
by the addition of tetracycline at 1 μg/ml in HMI-11 and SS1. The cells were counted 
every day and split to a density of 105 cells per ml. 
There was higher than expected variability between the two clones; but despite this, I 
observed a difference between the phenotypes in HMI-11 and serum on induction 
(Figure 9A). Due to the variation between the clones, I repeated this experiment. 
However, a loss of tetracycline control in one of the RNAi cell lines meant that the 
stem-loop RNAi could not be induced. However, this hit has since been validated 
independently in work by Cestari et al., who showed that IMP is non-essential in 
media, but essential in mouse models108. So it was not considered necessary to 
generate new RNAi cell lines and repeat this experiment. The most obvious hypothesis 
generated from these results is that synthesis of inositol from glucose via IMP (Figure 
9B) is not necessary for parasites in HMI-11 due to its overabundance of inositol 
compared to human serum (Table 1). 
The IMP gene was successfully tagged and verified by Western Blot (Figure 9C), 
although it migrated slower than expected (expected size 50 kDa). 
Immunofluorescence analysis appears to show localisation throughout the cytosol 
(Figure 9D). This localisation is also seen in the procyclic form via the TrypTag 
initiative121–123 (Appendix 1: RNAi Screen Hits; Figure 1, Table 6). This localisation is 
concurrent with a protein involved in inositol metabolism.  
 
 
 
 
 
FIGURE 9: IMP RNAI AND PROPOSED PATHWAY 
 
(A) Cumulative growth over six days of two independent RNAi strains targeting Tb927.5.2690. 
Error bars show standard deviation from the mean of two independently-generated biological 
clones. (B) A simple diagram showing proposed pathway which the RNAi interrupts. (C) Western 
Blot showing successful tagging of IMP in two separate clones. (D) IFA showing localisation of 
IMP. D1: Dapi, D2: 12-myc tagged IMP, D3: Combined. 
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RNAI TARGETING 5-METE LEADS TO LOSS OF FITNESS IN SS1 
The second gene tested for a serum growth defect was Tb927.8.2610, which encodes a 
putative 5-methyltetrahydropteroyltriglutamate-homocysteine S-methyltransferase (5-
MetE). There was little variability between the clones and a clear growth defect on 
tetracycline induction at 1 μg/ml which is not seen in HMI-11 (Figure 10A).  
5-MetE is required to convert 5-methyltetrahydrofolate into a form of folate which the 
trypanosome is able to utilise by removing the methyl group, which is then transferred 
to homocysteine to form methionine (Figure 10C). Either or both of these roles could 
be key in the gene’s essentiality in vivo because both methionine and folic acid are 
overabundant in HMI-11 compared to human blood (Table 1). Methionine levels are 
seven times higher than in blood and folic acid is three hundred times higher. 
Thymidine, which provides the parasite with a pathway that can bypass folate 
metabolism, is 805x times overabundant. Any of these nutrients could be key to the 
dispensability of this otherwise essential gene.  
In order to test these hypotheses, folate-free medium was prepared according to the 
standard recipe for HMI-11 with the omission of folic acid and thymidine. The growth 
curve was continued for eight days and the cells split to 104 / ml every 48 h. When this 
provided no phenotype (Figure 10B), it was repeated under the same conditions using 
methionine-free media prepared according to the standard HMI-11 recipe with the 
omission of methionine, folic acid and thymidine. Again, no phenotype was observed 
(Figure 10B). Given the possibility of other compensatory mechanisms, another 
experiment was designed to probe the system. Tagging for this gene was not 
successful.  
 
 
 
 
 
FIGURE 10: 5-METE RNAI AND PROPOSED PATHWAY 
 
Cumulative growth curves for RNAi strains targeting 5-MetE. Error bars show standard deviation 
from the mean of two independently-generated biological clones. (A) Cumulative growth over 
six days of two independent RNAi strains targeting Tb927.8.2610. (B) Cumulative growth 
following RNAi knockdown of 5-MetE in media lacking folate and thymidine (FDM) as well as 
media lacking folate, thymidine and methionine (MDM). (C) Simplified Folate/Methionine 
metabolism diagram showing the proposed action of 5-MetE which Tb927.8.2610 RNAi disrupts.  
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5-METE DEPLETION MAY BE RESCUED BY METABOLITE SUPPLEMENTATION 
The four supplements judged most likely to rescue the RNAi phenotype (Folic Acid, 
Glucose, Methionine, and Thymidine) were picked and growth curves carried out in 
duplicate for each singly and for all four combined. The supplements were added to 
the basic serum system containing thioglycerol and bathocuproinedisulfonic acid. 
Concentrations for each supplement were chosen to match the levels used in making 
HMI-11, in which I previously showed that there was no RNAi phenotype (Figure 10). 
As our hypothesis is that the enzyme is required to convert the folic acid found in 
serum and human blood to a useable form, forming methionine as a useful by-product 
of this process, we should expect an increase in viability under RNAi induction in SS1 
when grown with these supplements. 
Although the results trended in the expected direction (Figure 11), the RNAi cell line is 
not as responsive as previously observed (Figure 10A), and the results are not 
statistically significant. This is potentially due to loss of tetracycline control, something 
which has been observed in several laboratories with older RNAi strains. 
 
 
  
 
 
 
 
 
FIGURE 11: RESCUE OF RNAI PHENOTYPE IN SS1 
 
Rescue of RNAi phenotype using targeted supplementation of serum culture system. All growth 
curves generated at the same time under the same conditions. Solid lines show wild type data, 
dotted lines show induced RNAi targeting Tb927.8.2610. Error bars show standard deviation 
from the mean of two independently-generated biological clones. (A-E) Trypanosome growth in 
SS1 supplemented with 0.009 mM folic acid (D), 0.2 mM methionine (C), 0.16 mM thymidine (E) 
or all three in combination with glucose (B). (F) Total growth over the course of the experiment 
for each of the populations. Solid bars show uninduced, shaded bars show induced data.  
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DISCUSSION  
TRYPANOSOMES AND THE HOST 
African trypanosomes are extremely important pathogens due to the devastating 
societal and economic impact that they have in sub-Saharan Africa. If untreated, 
trypanosomiasis is fatal and the current treatment options are highly inadequate. In 
consequence, the development of new drugs and improved diagnostics is of vital 
importance. 
Our goal was to improve our understanding of the interplay between the host and the 
pathogen at the molecular level. We suspected that due to the differences between 
the culture media and the in vivo situation, many areas of potential drug discovery 
could have been missed in previous screening approaches. Therefore, we hoped that 
by increasing our understanding of T. brucei:host interactions, novel avenues of drug 
discovery could be uncovered. 
Past uses of high-throughput phenotyping approaches such as RNAi target sequencing 
(RIT-seq) to open up new aspects of trypanosome biology for further study have 
proved extremely effective. We therefore chose to use a genome-wide RNAi fragment 
library to probe for differences between the in vivo and in vitro essential gene sets. The 
unbiased approach given by RIT-seq is highly suited for investigation of an as yet 
unexplored area such as this. 
TRYPANOSOMES AND THE IMMUNE SYSTEM 
The African trypanosomes are strictly extracellular organisms. This has forced them to 
develop a complex array of anti-immune defences in order to prevent the host 
 
 
 
 
 
immune system from lysing them via trypanolytic factors43,44, antibody-mediated 
lysis124,56,57 and complement58,59. The trypanosome also has a range of processes which 
have been linked to general immunosuppression65–68,70 as well as defences against the 
adaptive immune response79. There remain a number of unanswered questions 
regarding immune interactions between the trypanosome and its human host. One of 
the key examples of this is the question of how the invariant surface glycoproteins and 
other large non-VSGs on the surface are protected from immune recognition. 
 
MONO-ALLELIC EXPRESSION AND VSG CONTROL 
Both GPI-PLC and DOT1B interact with the VSG pathway. GPI-PLC has been confirmed 
in the literature to have a role in virulence which is not required for growth in HMI-
1163,64. Finding this hit, therefore, increased our confidence in the results of our 
screen. GPI-PLC cleaves the GPI-anchors which attach the five million VSGs to the 
plasma membrane56,63. This releases them into the bloodstream during peak 
parasitaemia. The released VSGs then scavenge complement factors and antibodies. 
Potentially, this then allows a minority of the parasites to escape lysis by the immune 
system via the antibody-mediated complement activation pathway61,62. Therefore 
there is a clear hypothesis explaining why GPI-PLC influences parasitaemia in the 
murine model while remaining non-essential in the culture medium.  
DOT1B has also been independently confirmed to have no essentiality in vitro125. It has 
also been shown that dot1b-null strains show a ten-fold drop in growth over 72 h in a 
serum system and substantially reduced viability in a plating assay that is not reflected 
in HMI-11 (Lucy Glover, personal communication). DOT1B is a histone 
 
 
 
 
 
methyltransferase which is required for accurate nuclear division during 
differentiation126 and modulates the process of antigenic variation within the 
trypanosome. It has been shown that when the DOT1B gene is deleted, strict VSG 
silencing is no longer maintained and monoallelic transcription is compromised109. This 
creates an obvious survival burden on the trypanosome, as the strict integrity of its 
mono-allelic expression of the VSG genes is its greatest asset in avoiding antibody-
mediated lysis by the host immune system. That being said, the three-day time period 
of the initial screen would not allow enough time for an adaptive immune response to 
be mounted. DOT1B may well play another role in trypanosome infectivity which is 
equally crucial in the early stages of the infection and the presence of such a role could 
also explain why a serum-specific phenotype was observed over three days by Lucy 
Glover in her work. 
Although we have not tested GPI-PLC in SS1, we should be surprised to see a dramatic 
phenotype upon RNAi induction. This is because GPI-PLC appears to play a role directly 
in the parasite’s defences against the immune system, and therefore the lack of GPI-
PLC activity would not be expected to cause a growth defect in a system which, 
although closer to the in vivo nutrient balance, still lacks the host immune attack 
pathways. However, we were encouraged to see it in the in vivo screen results, where 
a specific phenotype was predictable based on previously published findings. 
  
 
 
 
 
 
TRYPANOSOMES IN CULTURE 
In an effort to understand and better treat sleeping sickness, bloodstream form T. 
brucei have been cultured in the laboratory setting since the 1970s. As detailed in the 
introduction to this work, these cultures originally required feeder layers of 
mammalian fibroblasts for continuous growth. The addition of various agents to IMDM 
allowed continuous culture without a feeder layer and formed HMI-11, now the 
standard routine cell culture medium for laboratory T. brucei strains95,96,98. However, 
while a convenient and comparatively economical option for routine lab work, HMI-11 
has been shown to create a problem for drug discovery and the requisite accurate 
understanding of the dispensability of trypanosome genes99,103. 
In order to address these problems, while seeking to minimise the use of animal 
models in our study, we have developed an in vitro system, SS1, which more closely 
matches the in vivo situation than the standard culture system. Our findings show that 
while it is more challenging than standard culture media, it is entirely possible to grow 
trypanosomes in this simple serum system providing both a copper chelator and a 
reducing agent are added. 
Although SS1 is truer to the host situation than even carefully designed media such as 
Creek’s Minimal Media, the limitations which it imposes on density do present 
challenges. Therefore, a more robust alternative would be useful. However, in my 
hands CMM proved ineffective.  
In attempting to develop more robust growth, one experiment indicated that the 
addition of cysteine to our serum system allowed more robust parasite growth (data 
 
 
 
 
 
not shown). This made sense within the historical context of T. brucei cell culture as 
cysteine was one of the first supplements added in transitioning to a system which 
allowed continuous growth without the presence of a human fibroblast feeder layer95. 
However, when I attempted to repeat this finding I saw initially high growth rates with 
subsequent declines and the death of the parasite cultures. Cysteine may still prove a 
valuable addition, but it may require increased levels of bathocuproinedisulfonic acid 
levels to buffer the increased cysteine and allow for healthy parasite growth. 
PHOSPHATIDYLINOSITOL SIGNALLING 
In their recent work chemo-genetically characterising the inositol phosphate pathway, 
Cestari et al. demonstrated that most of the steps in the pathway are essential for 
growth and that some of those which are not essential for growth in the lab are still 
essential for infection. One of the genes in the latter category was Tb927.5.2690, the 
gene which encodes the second of T. brucei’s inositol-1(or 4)-monophosphatases. A 
null strain was created by Cestari et al. which showed no growth defect in vitro. 
However, infectivity was reduced. Parasitaemia only rose to detectable levels nine 
days post-infection and the resurgent parasites grew 2.5-fold slower than wild type. 
The reduction in infectivity and reduced growth confirms what I found using our 
serum-based culture system. 
The precise molecular basis of Tb927.5.2690 dispensability in vitro is hard to determine 
because the product of the inositol monophosphatase enzyme that Tb927.5.2690 
encodes, inositol, plays a key role in complex signalling processes. Myoinositol is one of 
the noteworthy constituents of HMI-11 which is overabundant when compared to 
average levels in human blood99. The HMI-11 recipe contains 1.6x the levels of 
 
 
 
 
 
myoinositol found in human blood. Inositol is a key component which is required for 
glycosylphosphatidylinositol (GPI) synthesis127. GPI forms the anchor of the VSG and 
without the ability to synthesise it, the parasite would be unable to form the VSG coat 
and its defence against the host immune system would be dangerously compromised. 
Alternatively, in their earlier work, Cestari et al. noted that the inositol pathway 
appears to influence VSG expression at the telomeres128. If this pathway does regulate 
VSG expression then, again, a lack of myoinositol would compromise the anti-immune 
defences of the parasite. 
The IMP knockdown parasites seem capable of surviving on the exogenous myoinositol 
which is in excess in the media. However, with the reduced myoinositol levels in SS1, 
the IMP knockdown parasites struggle to survive. In the host itself, with its 
complement and antibody mediated lysis defences under attack, the parasites would 
be under even stronger pressure to synthesise myoinositol. 
FOLATE METABOLISM 
Folate is an essential nutrient for all organisms. It is required for the production and 
the maintenance of cells and for synthesising DNA and RNA. As such, it plays an 
especially important role in periods of high growth and rapid cell division. Insufficient 
folate will result in hindered DNA synthesis, cell division, RNA transcription and protein 
synthesis. 
In humans, folate deficiency has been linked to infertility129, heart disease and 
stroke130, as well as being connected to a number of foetal defects in folate-depleted 
mothers131,132. Due to folate’s huge public health importance, WHO placed it on their 
 
 
 
 
 
list of the “minimum medicine needs for a basic health-care system… the most 
efficacious, safe and cost–effective medicines for priority conditions”133. 
Folate is not generally found in the form of folic acid in the human body, with blood 
plasma levels being in the region of 0.02-0.08 μM in healthy adults134,135. Instead, the 
biological functions of folate are performed by various derivatives of tetrahydrofolate. 
The most common of these (and the primary source of folate in the circulatory system 
of the trypanosome’s host) is levomefolic acid, or 5-methyltetrahydrofolate (5-
MTHF)136. Within the cell, this can then be converted to tetrahydrofolate by various 
enzymes. 
5-METE 
5-methyltetrahydropteroyltriglutamate-homocysteine S-methyltransferase (5-MetE) is 
one such enzyme which is unique to T. brucei and which was one of the hits we 
pursued as part of our screen. 5-MetE catalyses the transfer of a methyl group from 5-
MTHF to L-homocysteine: forming tetrahydrofolate and methionine. As a result, it 
plays a key role in both folate metabolism and the de novo synthesis of methionine, 
both key processes for the parasite. 
Why is there such a strong phenotypic difference between depletion of 5-MetE in our 
serum system/in vivo screen compared to HMI-11? One hypothesis is that, as 
methionine is seven times overabundant in the HMI-11 recipe compared to human 
blood99, the presence of this excess methionine prevents the parasite having to 
synthesise methionine de novo, thus removing the need for this pathway and making 
the gene dispensable. A second hypothesis is that without the ability to convert the 
readily available 5-MTHF into tetrahydrofolate, the parasite cannot generate enough 
 
 
 
 
 
folate to sustain DNA synthesis and other processes which rely on sufficient folate 
levels for survival. In HMI-11 however, although there is a small source of 5-MTHF in 
the FBS, the main source is directly added folic acid – which is at a level three hundred 
times more abundant than the normal average in human blood. The parasite can, 
therefore, use this source of folate, bypassing the 5-MetE pathway in its entirety. 
These findings reflect what would be expected from the literature as compounds 
targeting folate metabolism have shown limited success in rich HMI-11 media while 
being extremely effective both in vivo and in folate-depleted media99,103. Folic acid can 
also outcompete classical antifolates for uptake into T. brucei137. Folic acid 
supplementation has also been shown to increase the risk of malaria to the extent that 
WHO reconsidered their recommendation of routine folate supplementation in 
affected areas138. 
It seems likely that the answer lies in a combination of the hypotheses detailed above. 
Unfortunately, there may be other compensatory mechanisms in rich media that are 
yet unknown. We designed a rescue experiment using our simple serum system 
supplemented with various nutrients, predicting that a combination of folate and/or 
methionine and/or thymidine would rescue the RNAi phenotype and restore normal 
growth. The experiment appeared compromised due to a reduced phenotype, 
although initial indications are promising. Further work is required to confirm the 
effect of these compounds, perhaps with a gene knockout which is not as susceptible 
to adaptation.  
 
 
 
 
 
IN VIVO VALIDATION 
No flask-based culture system can replicate the immune attack of the host. As a result 
of this limitation, we cannot completely discount any hits that do not validate in our 
simple serum system. However, we can rule out any that show a strong defect in HMI-
11. We can also use this system to validate those hits which show a phenotypic 
difference between HMI-11 and in vivo studies either entirely or partially due to the 
difference in nutrient levels between the in vivo and in vitro environments (such as 
IMP or 5-MetE). As a result, we can be confident that the hits which we have validated 
using SS1 are true hits. 
Demonstrating that our system is indeed an accurate representation of the in vivo 
environment will require animal studies in the future. However, the use of the SS1 
system will minimise the number of mice that will be required and reduce the costs 
and complexity of validating the results from this and future screens. 
  
 
 
 
 
 
FUTURE WORK 
PROTEIN BIOCHEMISTRY  
Utilisation of existing tagging vectors will allow localisation of the proteins encoded by 
our genes of interest and verification of knockdown119. We should expect to see 
proteins expressed on the cell surface and in the flagellar pocket, as these are most 
likely to be involved in host:parasite interactions. We should also expect several 
proteins to be secreted; and there may also be cytosolic proteins which are involved in 
metabolic processes specific to the in vivo situation. Localisation of these proteins 
using GFP or c-myc tags will give more information about their potential functions and 
guide our analysis. Data from ongoing whole-genome tagging approaches such as 
TrypTag121–123 will also be used to guide our approaches, although these may prove to 
be of limited direct relevance as, to date, high-throughput gene tagging is only possible 
in procyclic parasites. See Appendix 1, Table 6 for data available on TrypTag to date. 
CHARACTERISING HOST-PARASITE INTERACTIONS  
The initial workflow described above will be followed to characterise each new hit 
from the screen which we attempt to validate. Once it has been confirmed that 
depletion of the gene product causes a phenotype in SS1 which is not reflected in HMI-
11 then the process would depend on the suspected function of the gene product. 
If it was suspected from the bioinformatics data that the gene product had a role in 
metabolism in the host, then we would pursue this by metabolic studies. Using a 
minimal medium such as SS1 or CMM and comparing parasite survival rates at culture 
 
 
 
 
 
media levels of these specific metabolites or more physiological concentrations would 
help to validate the suspected purpose of the genes. 
If the genes were suspected to be involved in immune evasion in the host, then this 
would require the use of immunocompromised mice to verify the suspected function. 
However, other avenues would be investigated before committing to animal studies. If 
these studies prove appropriate at a later stage then a cohort of five control and five 
mutant mice would be used for each experiment. 
CAS9 AND GENOME EDITING  
The CRISPR-Cas9 system is based on the ‘adaptive immune defences’ of bacteria and 
archaea which exist to protect them against invading nucleic elements such as those 
from viruses139 or plasmids. RNA-guided nucleases such as Cas9 are reviewed in more 
detail here140.  
The CRISPR-Cas system would be ideal for validation of our genetic screen. As our hits 
are expected to be dispensable in vitro but essential in vivo, the generation of 
knockouts is possible, unlike for genes essential both in vitro and in vivo. Although it is 
possible to use RNAi techniques to knock down the genes of interest, and this is being 
used in the initial validation stage, knockout of the gene is much cleaner than a partial 
knockdown and guarantees complete removal of the gene. We do not yet have a 
robust system established for precise gene knockout using Cas9 in T. brucei, but this 
work is ongoing. 
  
 
 
 
 
 
APPENDIX 1: RNAI SCREEN HITS 
TABLE 5: LIST OF RNAI SCREEN HITS 
Gene ID 
(Tb927.) Gene Product 
RNAi Fold 
Change 
# 
TM SPP Putative Category 
1.3400 hypothetical protein, conserved 4.1 0 null Unknown 
1.4220 hypothetical protein, conserved 21.8 0 null RNA [a] 
1.570 DOT1B 18.6 0 null Surface, Cell Cycle 
2.3080 fatty acid desaturase, putative oleate desaturase, putative 4.4 6 null Metabolism 
2.3320 65 kDa ISG 5.1 1 0.62 Surface 
2.6000 GPI-PLC 4.7 0 null Surface 
3.2640 hypothetical protein, conserved 6.5 0 null Unknown 
4.1030 hypothetical protein, conserved 5.2 0 null Unknown 
4.2750 hypothetical protein, conserved 6.9 0 null Unknown 
4.3620 protein phosphatase 1, putative 5.0 0 null Protein Modification 
4.3630 protein phosphatase 1, putative 10.5 0 null Protein Modification 
4.4070 mevalonate kinase, putative 4.6 0 null Metabolism 
4.4340 hypothetical protein, conserved 5.0 0 null Unknown 
4.4770 hypothetical protein 16.6 1 0.28 Unknown 
5.2580 hypothetical protein, conserved 11.1 1 null Gene expression [b] 
5.2690 inositol-1(or 4)-monophosphatase 1, putative 10.4 0 null Metabolism, Signalling 
5.3000 hypothetical protein, conserved 6.7 1 null Metabolism [c] 
6.1640 single strand-specific nuclease, putative 11.2 0 0.98 DNA repair, Cell Cycle 
6.2140 hypothetical protein, conserved 28.1 0 0.62 Transport, RNA [d] 
6.2820 hypothetical protein, conserved 13.9 0 null Unknown 
6.2860 hypothetical protein, conserved 6.2 0 null Unknown 
6.4220 mitogen-activated protein kinase 5 5.6 0 null Stress Response 
6.4320 hypothetical protein, conserved 13.4 1 0.11 Unknown 
7.4090 serine/threonine-protein kinase, putative 6.4 0 null Protein Modification 
7.6700 hypothetical protein 14.2 0 null Unknown 
7.6820 hypothetical protein, conserved 7.4 0 null Unknown 
8.2230 Checkpoint protein HUS1, putative INF 0 null 
DNA repair, Stress 
Response, Cell Cycle 
8.2610 5-MetE, putative 6.4 0 null Metabolism 
8.6230 hypothetical protein, conserved 14.9 0 null Unknown 
9.9030 hypothetical protein, conserved 6.0 0 null Metabolism [e] 
10.12720 hypothetical protein, conserved 12.2 0 null Unknown 
10.13350 hypothetical protein, conserved 4.6 0 null Unknown 
10.14700 hypothetical protein, conserved 4.4 0 null Unknown 
10.14930 zinc finger protein family member, putative 739.5 0 null 
RNA, Protein 
Modification 
 
 
 
 
 
10.3880 hypothetical protein, conserved 5.9 1 null Unknown 
10.4260 hypothetical protein, conserved 7.3 10 0.90 Transport [f] 
10.5670 N-acetyltransferase subunit Nat1, putative 4.0 0 null Metabolism 
10.6610 chaperone protein DNAj, putative 5.2 1 null Stress response 
10.8730 hypothetical protein, conserved 5.8 0 0.98 Metabolism [g] 
11.13120 hypothetical protein, conserved 6.6 0 null Protein Modification [h] 
11.6560 hypothetical protein, conserved 40.8 0 null Unknown 
11.7380 
glycerol-3-phosphate 
dehydrogenase (FAD-dependent), 
mitochondrial 
5.7 0 0.60 Metabolism 
11.8400 Mitochondrial RNA processing endonuclease 1 (mRPN1) 6.7 0 null RNA 
11.890 hypothetical protein, conserved 4.5 0 1.00 Unknown 
11.9070 palmitoyl acyltransferase 4, putative 4.1 4 null Protein Modification 
List of hits from the RNAi in vivo screen. The three genes chosen for this project are highlighted 
in green. # TM refers to the number of transmembrane domains (by sequence similarity to 
existing known domains). SPP refers to the probability of the sequence containing a signal 
peptide (by sequence similarity to known domains). Putative categories determined by 
reference to similarity to existing protein families. 
 
CDD: Conserved domain database115,116, BLAST: Basic Local Alignment Search Tool113 
[a] CDD: RNase_H2-B superfamily 
[b] CDD:  PHA03307 family of transcriptional regulators 
[c] BLAST: thiopurine S-MTase; CCD: AdoMet_MTases superfamily 
[d] BLAST: decarboxylase; CCD: FAA_hydrolase superfamily 
[e] CDD: Glycosyltransferase family A 
[f] BLAST/CDD: LMBR family 
[g] BLAST: ubiquinone biosynthesis protein, ABC1 family/Phosphotransferase enzyme family; 
CDD: ABC1 kinase-like proteins, ABC1, Ubiquinone biosynthetic protein UbiB 
[h] CDD: PUB superfamily  
 
 
 
 
 
TABLE 6: TRYPTAG DATA FOR SCREEN HITS 
TrypTag localisation data. Shows data, where available from TrypTag121–123, regarding the 
localisation of hits from the screen. Genes from Table 5 above which are not present here have 
not been reported by the TrypTag project team to date. 
FIGURE 12: TRYPTAG IMAGE FOR IMP 
 
TrypTag image for IMP. Green = N-Terminally tagged IMP, Magenta = Dapi. 
  
Gene ID 
(Tb927.) Gene Product Tryptag Localisation 
1.4220 hypothetical protein, conserved Mitochondrion 
1.570 DOT1B Nuclear lumen (Cell cycle Dependent) 
4.1030 hypothetical protein, conserved nuclear lumen, cytoplasm 
4.2750 hypothetical protein, conserved cytoplasm (reticulated) 
4.3620 protein phosphatase 1, putative Cytoplasm (reticulated), axoneme (<10%, strong), cytoplasm (points, 25%) 
4.4070 mevalonate kinase, putative Glycosome (75%) 
5.2690 inositol-1(or 4)-monophosphatase 1, putative 
Cytoplasm, flagellar cytoplasm, nuclear 
lumen 
6.2860 hypothetical protein, conserved cytoplasm (points) 
10.12720 hypothetical protein, conserved hook complex 
10.14700 hypothetical protein, conserved Cytoplasm, nucleoplasm, nucleolus (strong) 
10.14930 zinc finger protein family member, putative acidocalcisome 
10.3880 hypothetical protein, conserved cytoplasm (points, reticulated) 
10.5670 N-acetyltransferase subunit Nat1, putative cytoplasm 
11.6560 hypothetical protein, conserved basal body, pro-basal body 
11.8400 Mitochondrial RNA processing endonuclease 1 (mRPN1) cytoplasm (points) 
11.890 hypothetical protein, conserved cytoplasm (weak), endocytic 
 
 
 
 
 
APPENDIX 2: AUTONOMOUSLY REPLICATING SEQUENCE SCREEN 
INTRODUCTION 
Study of Trypanosoma brucei is hampered by a lack of genetic tools. One such missing 
tool is access to autonomously replicating sequences for episomal replication. One 
study found a few autonomously replicating plasmids in procyclic form T. brucei. These 
could exist as highly stable single-copy episomes within the parasite141 and proved 
useful in characterising elements of trypanosomal DNA replication142. During my 
rotation, I aimed to create a vector which would enable whole genome screening in 
bloodstream form trypanosomes in order to find and characterise these sequences. 
METHODS AND RESULTS 
To accomplish this goal, the LacZ stuffer fragment from pRPaiSL was amplified and 
digested with SacI / EcoRV. It was then cloned into SacI / NaeI digested pGEM-T easy. 
The NPT resistance cassette was amplified from p5’neo5’ and digested with EcoRI and 
ligated to a T7 terminator with sticky ends for EcoR1 and XbaI before being digested 
with SacII with the aim of cloning it into SacII / XbaI digested vector. 
Synthesising the T7 terminator within the NPT primer proved unworkable. Instead, the 
T7 terminator was inserted as a pair of annealed primers which were ligated to the 
NPT PCR product before it was inserted into the vector. I successfully amplified the 
LacZ stuffer fragment (Figure 13A) and completed cloning step one (Figure 13B). I also 
successfully amplified the NPT cassette (Figure 13C) and ligated it to the T7 terminator 
(Figure 13D). However, the final ligations of the NPT cassette to the vector were 
unsuccessful.  
 
 
 
 
 
FIGURE 13: CLONING RESULTS 
 
Cloning results. (A) Left to right – Ladder and LacZ PCR product; (B) results of LacZ-pGEM-T Easy 
ligation, samples 2, 3 and 6 showing expected band (1,100bp), sequenced to verify; (C) Left to 
right – Ladder, NPT PCR product, NPT PCR product; (D) Left to right – Ladder, NPT, NPT ligated 
to T7 terminator 
  
 
 
 
 
 
CONCLUSION 
We aimed to create a vector which would allow us to screen the trypanosome genome 
for autonomously replicating sequences in order to further characterise the nature of 
these sites and hopefully create new genetic tools. The vector was not completed but 
several important obstacles were surmounted and the first stage of the cloning 
process was successful. The PCR amplification of the NPT cassette, a major bottleneck 
in the cloning strategy, was successfully optimised. I also successfully ligated the NPT 
cassette to the T7 terminator and verified this by running the ligation on an agarose 
gel. However, the ligation of this to the vector created in the first cloning step proved 
challenging. Subsequently, the decision was taken to synthesise this vector instead of 
attempting to construct it via enzyme digests. 
 
 
 
 
  
 
 
 
 
 
APPENDIX 3: QUORUM SENSING 
INTRODUCTION 
Quorum sensing is the mechanism by which organisms communicate at high cell 
density and is used by many species to control differentiation, forming part of their 
response to the environment. Quorum sensing normally involves the production of 
small, extracellular signalling molecules called autoinducers (AIs). AIs are then 
detected by other members of the species, triggering the desired response. Quorum 
sensing has been most closely studied in bacteria, where it has been linked to many 
processes such as bioluminescence, sporulation, antibiotic production and virulence 
factor secretion, to name a few143. A feed forward loop is normally created by the 
reception of the AIs stimulating their production – thus enabling a rapid and 
synchronous response. Although the molecular details of the AIs and the feed forward 
loop vary greatly from system to system, the basic principles are the same across many 
organisms.  
Compared to other species, quorum sensing systems in trypanosomes are quite poorly 
understood. What is known from research over the last two decades is that 
differentiation and density sensing are controlled via a cyclic AMP-linked stumpy 
induction factor (SIF)144, which is thought to be soluble, heat stable and of low 
molecular weight.  
A recent genome-wide RNA interference library screen looking for resistance to the 
Phosphodiesterase Inhibitor CpdA identified the first downstream cAMP effector 
proteins found in T. brucei145. A second screen was used to identify the signalling 
 
 
 
 
 
components driving stumpy formation in order to shed some light on genes which may 
be involved in quorum sensing mechanisms in trypanosomes146. This latter study 
looked for genes which, when knocked down, made the trypanosomes unresponsive 
to cell-permeable analogues of cyclic AMP. It provided an initial identification of some 
of the molecules and processes required for T. brucei differentiation and opened up 
some new potential targets for future drug discovery.  
Prior to these screens, a RIT-seq screen was carried out by our lab which showed a 
gene with a distinct gain of fitness phenotype at high density107. This was confirmed by 
a subsequent unpublished screen carried out by Sam Alsford. The hits from this screen 
did not overlap with the data sets mentioned above and five of the nine key hits had a 
connection to calcium or the calcium-binding messenger protein calmodulin, which 
indicates a role in a separate, calcium-dependent pathway. 
I aimed to investigate this gene and to understand the relation of the gene and the 
potential wider calcium-mediated density based signalling mechanism to the classical 
SIF pathway. 
METHODS AND RESULTS  
Density sensing proteins were discovered and confirmed by Sam Alsford using the 
RNAi library screening methods previously described107. The gene was cloned using 
high-fidelity PCR and cloned into pRPaiSL to generate an untagged overexpression 
construct117. For tagging at the native loci, an N-terminal fragment was amplified and 
cloned into pNATTAGx 117.  
 
 
 
 
 
For the growth curve, 2T1 cells were seeded at 105 cells per ml every day. From this 
culture, a feeder flask was seeded daily at 5x105 cells per ml. After 24 h this feeder 
flask was spun down and the media filtered to provide conditioned media for the 
growth curve in order to boost the levels of the signal received (or mediated) by the 
product of this quorum sensing gene. Two independent biological clones of the over-
expresser strain were split and seeded at 105 cells/ml in this media. The cells were 
counted every 24 hours using a haemocytometer and diluted as appropriate. Induction 
was by tetracycline at 1 μg/ml. After five days of splitting these cells in this conditioned 
medium a difference was observed between the over-expresser and the 2T1 control. 
One of the two independent biological clones appears to have adapted as it grew out 
on the last day, skewing the results, but the indication is that overexpression of 
Tb927.8.6870 makes the parasite more sensitive to conditioned media (Figure 14).  
 
 
 
 
 
FIGURE 14: OVER-EXPRESSER SHOWS SLIGHTLY INCREASED DEFECT IN 
CONDITIONED MEDIA 
 
Growth curve using conditioned media and an over-expression cell line to probe quorum 
sensing mechanisms in T. brucei. Error bars show standard deviation from the mean between 
two independently-generated biological clones. 
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CONCLUSION 
Many organisms, including the trypanosomes, use density-sensing mechanisms to 
communicate and synchronise beneficial behaviours. As a blood-borne parasite with a 
complex life cycle requiring adaptation between stages, this is particularly important 
for T. brucei. 
Our unpublished RIT-seq screen (Sam Alsford) showed multiple hits which conferred a 
gain of fitness at high density. Over 70% of these reads fell on a single gene. The hits, 
however, did not overlap with the pre-existing data sets, indicating that this protein is 
not part of the canonical SIF pathway, although the pathways may well intersect. This 
is backed up by the number of hits in the screen which had a connection to calcium or 
calmodulin.  
One of the RNAi target fragments that were picked out of the screen actually hits the 
gene next to Tb927.8.6870. Interestingly, based on homology, this gene is thought to 
be a dauer formation protein. Dauer (German for endurance) proteins are known in C. 
elegans to be involved in the progression to a quiescent state that allows the worm to 
survive harsh conditions. It is tempting to hypothesise that this protein is an effector 
which is triggered by the quorum sensor we have discovered.  
Unfortunately, Tb927.8.6870 knockout strains made by Sam Alsford did not replicate 
the phenotype seen in the screen. This could be due to adaptation and we are making 
inducible RNAi strains to address this problem. We hope to repeat our experiment 
using the null strains and these new RNAi strains in addition to the over-expresser. 
 
 
 
 
 
Calcium sensors such as aequorin and pericam would also help to probe the link to 
calcium.  
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